Modulation of heart fibroblast migration and collagen gel contraction by IGF-I.
Dynamic interactions between cells and the extracellular matrix are essential in the regulation of a number of cellular processes including migration, adhesion, proliferation and differentiation. A variety of factors have been identified which modulate these interactions including transforming growth factor-beta, platelet-derived growth factor and others. Insulin-like growth factors have been shown to regulate collagen production by heart fibroblasts; however, the effects of this growth factor on the interactions of heart fibroblasts with the extracellular matrix have not been examined. The present studies were carried out to determine the effects of IGF-I on the ability of fibroblasts to interact with the extracellular matrix and to begin to determine the mechanisms of this response. These experiments illustrate that IGF-I treatment results in increased migration, collagen reorganization and gel contraction by heart fibroblasts. IGF-I has been shown to activate both the mitogen-activated protein kinase and phophatidylinositol-3 kinase pathways in isolated cells. Experiments with pharmacological antagonists of these pathways indicate that the mitogen-activated protein kinase pathway is essential for IGF-I stimulated collagen gel contraction by fibroblasts. These studies illustrate that IGF-I modulates the ability of fibroblasts to interact with the collagen matrix and that activation of multiple signaling pathways by IGF-I may produce distinct downstream responses in these cells.
Kanekar
S
S
Department of Developmental Biology and Anatomy, University of South Carolina, School of Medicine, Columbia 29208, USA.
Borg
T K
TK
Terracio
L
L
Carver
W
W
D000818:Animals; D000831:Animals, Newborn; D015703:Antigens, CD / Q000096:biosynthesis / Q000378:metabolism; D002448:Cell Adhesion / Q000187:drug effects; D002465:Cell Movement / Q000187:drug effects*; D002867:Chromones / Q000494:pharmacology; D003094:Collagen; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005109:Extracellular Matrix / Q000201:enzymology; D005260:Female; D005347:Fibroblasts / Q000166:cytology / Q000201:enzymology; D005419:Flavonoids / Q000494:pharmacology; D005782:Gels; D007334:Insulin-Like Growth Factor I / Q000494:pharmacology*; D039564:Integrin alphaV; D019012:Integrin beta1 / Q000096:biosynthesis / Q000378:metabolism; D020782:Matrix Metalloproteinases / Q000378:metabolism; D009025:Morpholines / Q000494:pharmacology; D009206:Myocardium / Q000166:cytology* / Q000201:enzymology*; D011247:Pregnancy; D011505:Protein-Tyrosine Kinases / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D019030:Receptors, Vitronectin / Q000096:biosynthesis / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology
D015703:Antigens, CD; D002867:Chromones; D004791:Enzyme Inhibitors; D005419:Flavonoids; D005782:Gels; D039564:Integrin alphaV; D019012:Integrin beta1; D009025:Morpholines; D019030:Receptors, Vitronectin; C085911:2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; D007334:Insulin-Like Growth Factor I; D003094:Collagen; D011505:Protein-Tyrosine Kinases; D020782:Matrix Metalloproteinases; C093973:2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one